Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone

Expert Opinion on Investigational Drugs
Clifford J BaileyPeter R Flatt

Abstract

Type 2 diabetes is typically associated with insulin resistance and dysfunction of insulin-secreting pancreatic beta-cells. Addressing these defects often requires therapy with a combination of differently acting antidiabetic agents. A potential novel combination in development brings together the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin with the thiazolidinedione pioglitazone into a fixed-dose single-tablet combination. The former component acts mainly to increase prandial insulin secretion; the latter improves insulin sensitivity. To date, clinical trials conducted in type 2 diabetes patients have used combinations of sitagliptin (100 mg/day) and pioglitazone (30 - 45 mg/day) as separate tablets. These trials have shown that the combinations offer additive efficacy in reducing blood glucose when given as initial antidiabetic therapy and as add-on therapy when pioglitazone alone fails to maintain glycemic control. Initial therapy with a combination of sitagliptin (100 mg/day) and pioglitazone (30 mg/day) reduced HbA1c by > 2% starting from a baseline > 9%. Adding sitagliptin (50 - 100 mg/day) to patients inadequately controlled on pioglitazone reduced HbA1c by 0.7 - 1.4% from a baseline of 8 - 8.5%. The combination...Continue Reading

References

Feb 29, 1996·The New England Journal of Medicine·C J Bailey, R C Turner
Jul 24, 2002·Diabetologia·A LieblUNKNOWN ODE-2 Advisory Board
Aug 28, 2004·Diabetes·Carolyn F Deacon
Sep 10, 2004·The New England Journal of Medicine·Hannele Yki-Järvinen
Jul 28, 2005·Diabetes·Bart Staels, Jean-Charles Fruchart
Nov 25, 2005·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Clifford J Bailey
Mar 28, 2006·Biochemical and Biophysical Research Communications·Henrike SellJürgen Eckel
Jul 25, 2007·Diabetes, Obesity & Metabolism·Michael DeckerAlan N Elias
Oct 16, 2007·Diabetes Care·Thomas J HoergerJinan B Saaddine
May 30, 2008·Frontiers in Bioscience : a Journal and Virtual Library·Peter R FlattBrian D Green
Jun 4, 2008·Diabetes, Obesity & Metabolism·J C N ChanD Williams-Herman
Oct 9, 2008·Drugs·Andrew J KrentzClifford J Bailey
Jan 30, 2009·Diabetes, Obesity & Metabolism·C J Bailey, C Day
Mar 12, 2009·Current Drug Metabolism·P R FlattB D Green
Aug 12, 2009·Archives of Internal Medicine·Colin R DormuthJames M Wright
Aug 13, 2009·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Keith G TolmanAlfonso Perez
Dec 18, 2009·Metabolism: Clinical and Experimental·Giuseppe DerosaArrigo F G Cicero
Jan 29, 2010·Diabetes Care·UNKNOWN American Diabetes Association
Apr 7, 2010·The American Journal of Medicine·Richard M BergenstalDavid M Kendall
Apr 24, 2010·Journal of the American College of Cardiology·Sanjay KaulUNKNOWN American College Of Cardiology Foundation

❮ Previous
Next ❯

Citations

Jul 13, 2011·Experimental Diabetes Research·Ilaria DicembriniCarlo Maria Rotella
Jun 7, 2011·Expert Opinion on Pharmacotherapy·Thomas ForstAndreas Pfützner
May 6, 2015·Expert Opinion on Drug Metabolism & Toxicology·André J Scheen
Dec 30, 2011·The American Journal of the Medical Sciences·William T Cefalu
Jan 1, 2013·Journal of Drug Assessment·Niki KatsikiAsterios Karagiannis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.